SEC Form 4 · accession 0001507650-26-000007
Summit Therapeutics Inc. · SMMT
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Mahkam Zanganeh
Officer — Co-Chief Executive Officer · Director · 10% Owner
Period of report
Jun 12, 2026
Accepted (ET)
Jun 12, 2026 · 2:35 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001599298
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Jun 12, 2026 | P | 3,810,000 | $13.12 | A | 573,883,879 | I | By Spouse |
| Common StockF1 | holding | — | — | — | 25,824,474 | I | By the Mahkam Zanganeh Revocable Trust, with the Reporting Person as Trustee | |
| Common StockF1 | holding | — | — | — | 76,680 | I | Immediate family member | |
| Common StockF1 | holding | — | — | — | 10,199,776 | I | By the Shaun Zanganeh Irrevocable Trust, with the Reporting Person as Trustee | |
| Common Stock | holding | — | — | — | 31,000 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The Reporting Person disclaims beneficial ownership of these securities, except to the extent of her pecuniary interest therein, if any, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 or for any other purpose.